Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335423 | 0.89 | CYP1A2 (0.63) | CYP1A2CYP2C9ALDH1A1KDM4ERAB9A | |
| SCHEMBL10516211 | 0.84 | CYP1A2 (0.58) | CYP1A2CYP2C9ALDH1A1KDM4EMAPT | |
| SCHEMBL1162273 | 0.83 | FKBP1A (0.41) | CYP1A2ALDH1A1KDM4ERAB9AMAPT | |
| SCHEMBL19433083 | 0.83 | CYP1A2 (0.59) | CYP1A2CYP2C9KDM4ESMN1; SMN2APOBEC3A | |
| Ethylbenzene SCHEMBL7167647 | 0.82 | CYP1A2 (0.71) | CYP1A2CYP2C9ALDH1A1KDM4EMAPT | |
| P-Xylene SCHEMBL3752326 | 0.81 | CYP1A2 (0.70) | CYP1A2CYP2C9ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL2729317 | 0.81 | CYP1A2 (0.80) | CYP1A2CYP2C9ALDH1A1KDM4EGAA | |
| Sulfuric Acid SCHEMBL31183034 | 0.81 | CYP1A2 (0.84) | CYP1A2CYP2C9ALDH1A1KDM4EGAA | |
| SCHEMBL7072020 | 0.81 | CYP1A2 (0.59) | CYP1A2CYP2C9ALDH1A1RAB9AMAPT | |
| SCHEMBL10387619 | 0.80 | CYP1A2 (0.61) | CYP1A2CYP2C9ALDH1A1PDE4DPDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462439-B1 | STABILIZED OPEN FORM TRANSGLUTAMINASE AS A DIAGNOSTIC INDICATOR FOR AUTOIMMUNE DISEASES | ZEDIRA GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-2461847-B1 | DEVICE FOR ELIMINATING BIOLOGICALLY HARMFUL SUBSTANCES FROM BODILY FLUIDS | HEMOTEQ AG (DE) | 2015-05-27 | — | — | EP | disclosed |
| US-8808980-B2 | Stabilized open form transglutaminase as a diagnostic indictor for autoimmune diseases | ZEDIRA GMBH (DE) | 2014-08-19 | — | — | US | disclosed |
| US-20120315262-A1 | STABILIZED OPEN FORM TRANSGLUTAMINASE AS A DIAGNOSTIC INDICTOR FOR AUTOIMMUNE DISEASES | ZEDIRA GMBH (DE) | 2012-12-13 | — | — | US | disclosed |
| EP-2462439-A1 | STABILIZED OPEN FORM TRANSGLUTAMINASE AS A DIAGNOSTIC INDICATOR FOR AUTOIMMUNE DISEASES | Zedira GmbH (DE) | 2012-06-13 | — | — | EP | disclosed |
| EP-2461847-A1 | DEVICE AND METHOD FOR ELIMINATING BIOLOGICALLY HARMFUL SUBSTANCES FROM BODILY FLUIDS | Hemoteq AG (DE) | 2012-06-13 | — | — | EP | disclosed |
| WO-2011057826-A1 | STABILIZED OPEN FORM TRANSGLUTAMINASE AS A DIAGNOSTIC INDICATOR FOR AUTOIMMUNE DISEASES | ZEDIRA GMBH (DE) | 2011-05-19 | — | — | WO | disclosed |
| EP-1326708-B1 | ADSORBENT HAVING DIFFERENTLY MODIFIED SURFACE AREAS, METHOD FOR THE PRODUCTION THEREOF AND USE OF THE SAME | FRESENIUS MEDICAL CARE DE GMBH (DE) | 2006-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120315262-A1 | STABILIZED OPEN FORM TRANSGLUTAMINASE AS A DIAGNOSTIC INDICTOR FOR AUTOIMMUNE DISEASES | TGM2, TGM3, TGM6 | CYP1A2 4594/4885CYP2C9 4417/4885ALDH1A1 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.